- Home
- HBB vs MOLN Comparison
HBB vs MOLN Comparison
Compare HBB & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- MOLN
- Stock Information
- Founded
- HBB 1904
- MOLN 2004
- Country
- HBB United States
- MOLN Switzerland
- Employees
- HBB N/A
- MOLN N/A
- Industry
- HBB Home Furnishings
- MOLN
- Sector
- HBB Consumer Discretionary
- MOLN
- Exchange
- HBB Nasdaq
- MOLN Nasdaq
- Market Cap
- HBB 230.7M
- MOLN 195.4M
- IPO Year
- HBB 2017
- MOLN 2021
- Fundamental
- Price
- HBB $16.60
- MOLN $4.87
- Analyst Decision
- HBB
- MOLN
- Analyst Count
- HBB 0
- MOLN 0
- Target Price
- HBB N/A
- MOLN N/A
- AVG Volume (30 Days)
- HBB 59.8K
- MOLN 17.9K
- Earning Date
- HBB 10-30-2024
- MOLN 08-26-2024
- Dividend Yield
- HBB 2.74%
- MOLN N/A
- EPS Growth
- HBB 107.04
- MOLN N/A
- EPS
- HBB 1.88
- MOLN N/A
- Revenue
- HBB $647,834,000.00
- MOLN $7,105,397.00
- Revenue This Year
- HBB $4.60
- MOLN N/A
- Revenue Next Year
- HBB N/A
- MOLN $29.41
- P/E Ratio
- HBB $8.83
- MOLN N/A
- Revenue Growth
- HBB 5.30
- MOLN N/A
- 52 Week Low
- HBB $14.34
- MOLN $3.32
- 52 Week High
- HBB $31.78
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- HBB 35.56
- MOLN 38.68
- Support Level
- HBB $16.00
- MOLN $4.75
- Resistance Level
- HBB $17.14
- MOLN $5.20
- Average True Range (ATR)
- HBB 0.82
- MOLN 0.14
- MACD
- HBB 0.18
- MOLN -0.05
- Stochastic Oscillator
- HBB 27.35
- MOLN 17.13
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.